EC Number |
Inhibitors |
Structure |
---|
3.4.24.84 | 1,10-phenanthroline |
Zn2+ chelator |
|
3.4.24.84 | atazanavir |
- |
|
3.4.24.84 | benzyloxycarbonyl-Phe-Ala-2,4,6-trimethylbenzoyloxymethyl ketone |
0.25 mM, 21% inhibition, inhibition is not reversible |
|
3.4.24.84 | benzyloxycarbonyl-Phe-Ala-2,4,6-trimethylbenzoyloxymethyl ketone |
0.25 mM, 41% inhibition, inhibition is not reversible |
|
3.4.24.84 | benzyloxycarbonyl-Phe-Ala-2,4,6-trimethylbenzoyloxymethyl ketone |
0.25 mM, 22% inhibition, inhibition is not reversible |
|
3.4.24.84 | benzyloxycarbonyl-Phe-Lys-2,4,6-trimethylbenzoyloxymethyl ketone |
0.25 mM, 76% inhibition, inhibition is not reversible |
|
3.4.24.84 | benzyloxycarbonyl-Phe-Lys-2,4,6-trimethylbenzoyloxymethyl ketone |
0.25 mM, 68% inhibition, inhibition is not reversible |
|
3.4.24.84 | darunavir |
- |
|
3.4.24.84 | lopinavir |
HIV protease inhibitors inhibit ZMPSTE24, leading to an accumulation of farnesyl-prelamin A. The inhibition of ZMPSTE24 by HIV protease inhibitors could play a role in the side effects of these drugs |
|
3.4.24.84 | lopinavir |
- |
|